Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Gonzalez-Cao, M; Berciano-Guerrero, MA; Muñoz-Couselo, E; Manzano, JL; Cerezuela-Fuentes, P; Crespo, G; Soria, A; de Miguel, PA; Sanz, LG; de la Rosa, CA; Castaño, AG; Puértolas, T; Espinosa, E; Medina, J; Bellido, L; Berrocal, A; Majem, M; Castro, RL; Fernandez, LA; Garcia, F; de la Borbolla, MR; Algarra, SM; Márquez-Rodas, I.

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04018-5]

Rha, SY; Castanon, E; Gill, S; Senellart, H; Lopez, J; Marquez-Rodas, I; Victoria, I; Kim, TM; Lwin, Z; Burger, MC; Simonelli, M; Cassier, PA; Hendifar, AE; Ascierto, PA; Dutcus, C; Okpara, CE; Ghori, R; Jin, F; Groisberg, R; Villanueva, L.

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort

CANCER. 2025; 131(16): [doi:10.1002/cncr.70015]

García-Alfonso, P; Alcaide-Garcia, J; Aguilar, EA; Elez, E; Montes, AF; Escobar, IG; Grávalos, C; García, IM; Viladot, CM; Vivas, CS; Sastre, J; Tarazona, N; Jimenez-Fonseca, P.

Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensus

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-03986-y]

García, LF; Conde, E; Hernandez, S; Alonso, M; Curto, D; Dómine, M; Rojo, F; Freire, J; Gómez-Román, J; Calles, A; Cebollero, M; González-Larriba, JL; Saiz, M; Esteban, I; Gutiérrez, L; Lopez-Rios, F; de Castro, J.

PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significance

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04013-w]

Arranz, JA; Martínez, C; Gallego, L; Heredero, A; Rebollo, P; Fernández, L; Estella, E; Larena, DV; Palomar, V.

Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study

Future Oncology. 2025; 21(21): 2767-2774 [doi:10.1080/14796694.2025.2542030]

Villacampa, G; Pascual, T; Tarantino, P; Cortés, J; Perez-Garcia, J; Llombart-Cussac, A; Conte, P; Mancino, M; Guarneri, V; Dieci, MV; Waks, AG; Schettini, F; Brasó-Maristany, F; Griguolo, G; de Castro, B; Reboredo, C; Antolin, S; Bueno-Muiño, C; Echavarria, I; López-Tarruella, S; Massarrah, T; del Monte-Millán, M; Martin, M; Buckingham, W; Parker, JS; Vivancos, A; Polyak, K; Metzger, O; Cwolff, A; Demichele, A; Tung, NM; Perou, CM; Paré, L; Villagrasa, P; Prat, A; Tolaney, SM.

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

LANCET ONCOLOGY. 2025; 26(8): [doi:10.1016/S1470-2045(25)00276-1]

Graff, JN; Burotto, M; Fong, PC; Pook, DW; Zurawski, B; Kopp, RM; Salinas, J; Bylow, KA; Kramer, G; Ratta, R; Kwiatkowski, M; Retz, M; Kwak, C; Arija, JAA; Gurney, H; Matsubara, N; Villanueva, L; Todenhöfer, T; Liang, LW; Todoric, J; Imai, K; Stenzl, A.

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study

ANNALS OF ONCOLOGY. 2025; 36(8): 976-987 [doi:10.1016/j.annonc.2025.05.007]

Cherny, NI; Oosting, SF; Dafni, U; Latino, NJ; Galotti, M; Zygoura, P; Dimopoulou, G; Amaral, T; Barriuso, J; Calles, A; Kiesewetter, B; Gomez-Roca, C; Gyawali, B; Piccart, M; Passaro, A; Roitberg, F; Tarazona, N; Trapani, D; Curigliano, G; Wester, R; Zarkavelis, G; Zielinski, C; Vries, EGED.

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)

ANNALS OF ONCOLOGY. 2025; 36(8): 866-908 Nº de citas: 2 [doi:10.1016/j.annonc.2025.04.006]

Toledano-Fonseca, M; Cano-Osuna, MT; Elez, E; Soto-Alsar, J; Paáez, D; Fernández-Montes, A; Graña, B; Salud, A; Yubero, A; Macías, I; Quintero, G; López-López, C; Fernández-Rodríguez, T; García-Ortiz, MV; Sastre, J; García-Alfonso, P; Rodríguez-Ariza, A; Aranda, E.

Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2025; : [doi:10.1111/eci.70103]

Ayala-de Miguel, P; Muñoz-Couselo, E; Gutiérrez-Sanz, L; Fernández, LA; Navarro-Pérez, V; Berciano-Guerrero, MA; García-Arroyo, F; de la Rosa, C; Cerezuela-Fuentes, P; Majem, M; Campos-Balea, B; Soria, A; Hernández-Marín, B; García-Castaño, A; Martin-Algarra, S; Marquez-Rodas, I.

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04005-w]

Stecklein, SR; Martin, M; Villacampa, G; del Monte-Millan, M; Yoder, R; Pathak, H; Cobo, S; Brasó-Maristany, F; Alvarez, EL; Echavarría, I; Bueno-Muiño, C; Jerez, Y; Cebollero, M; Bueno, O; García-Saenz, JA; Moreno, F; Gómez, HL; Massarrah, T; Herrero, B; Paré, L; Marín-Aguilera, M; Buckingham, W; López-Tarruella, S; Villagrasa, P; Godwin, AK; Salgado, R; Prat, A; Sharma, P.

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; : [doi:10.1093/jnci/djaf162]

Alfano, F; Navas, P; Lamata, P; García, KF; Ortuño, JE; Zamora, OB; Lizarraga, S; Santos, A; Pascau, J; Goicolea, JM; Ledesma-Carbayo, MJ.

Patient-specific visco-hyperelastic mechanical model for breast tumor localization in surgical planning

Bioengineering & Translational Medicine. 2025; : [doi:10.1002/btm2.70044]

Calles, A; Navarro, A; Uribe, BGDD; Colomé, EA; de Miguel, M; Alvarez, R; Arregui, M; Moreno, V; Rocha, P; Calvo, E; Ramon-Patino, J; de la Fuente, EC; Alcalá-López, D; Boix, O; Fernández-Pinto, M; Rodríguez-Morató, J; Palmero, R; Nadal, E; Jove, M; Felip, E.

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study

JOURNAL OF THORACIC ONCOLOGY. 2025; 20(7): 969-982 Nº de citas: 4 [doi:10.1016/j.jtho.2025.02.005]

Felip, E; Rojas, CI; Schenker, M; Kowalski, DM; Casarini, IA; Csöszi, T; Sendur, MAN; Martins, J; Blanco, AC; Wang, C; Wang, M; Fallas, RALR; Yoshioka, H; Nair, S; Song, X; Deng, X; Lala, M; Eiras, R; Takahashi, T.

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

ANNALS OF ONCOLOGY. 2025; 36(7): 775-785 [doi:10.1016/j.annonc.2025.03.012]

Vedovati, MC; Martín, AJM; Giustozzi, M; Jimenez-Fonseca, P; Becattini, C; del Prado, MPM; Dentali, F; Huisman, M; Cohen, AT; Bauersachs, R; Carmona-Bayonas, A; Agnelli, G.

Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism

EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2025; 137: 67-72 Nº de citas: 1 [doi:10.1016/j.ejim.2025.04.016]

Adrián SG; Pérez CI; Carmona-Bayonas A; Morán LO; Pérez JR; Del Prado PM; De Castro EM; Neria F; Pérez IF; De Herreros MG; Campos MC; Escobar IG; Balanyà RP; González DM; Fonseca PJ; García MEG; Cánovas MS; Langa JM; Segura PP; Vidal MJM; Martín AJM.

Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding.

HAEMATOLOGICA. 2025; 110(7): 1513-1522 Nº de citas: 1 [doi:10.3324/haematol.2024.286152]

Chi, KN; Mckay, RR; Sandhu, S; Arranz, JA; Barthelemy, P; Hadaschik, B; Matsubara, N; Shore, ND; Ye, DW; Cascella, T; Irincheeva, I; Kreiser, S; Thiery-Vuillemin, A; Rathkopf, DE.

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC

Future Oncology. 2025; 21(14): 1771-1777 [doi:10.1080/14796694.2025.2502318]

Calles A; Calvo E; Santamaría Nuñez G; Costanzo F; Guillén MJ; Martinez Diez M; Gupta A; Cuevas C; Egly JM; Aviles P.

Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.

MOLECULAR CANCER THERAPEUTICS. 2025; 24(6): 828-839 Nº de citas: 1 [doi:10.1158/1535-7163.MCT-24-0050]